Processa Pharmaceuticals, Inc. (PCSA)

Market Cap	6.94M +110.4%
Revenue (ttm)	n/a
Net Income	-14.11M
EPS	-7.54
Shares Out	2.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,348
Open	2.580
Previous Close	2.650
Day's Range	2.580 - 2.730
52-Week Range	1.760 - 19.635
Beta	1.01
Analysts	Strong Buy
Price Target	25.00 (+857.85%)
Earnings Date	May 7, 2026

About PCSA

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metasta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: PCSA

Analyst Summary

According to one analyst, the rating for PCSA stock is "Strong Buy" and the 12-month stock price target is $25.0.

Price Target

$25.0

(857.85% upside)

Analyst Consensus: Strong Buy